Tennessee is currently home to 1989 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
NCT04816526
Recruiting
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2022
Locations: Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee
Conditions: Myeloma Multiple
Register for Updates
Real-Time Muscle Pressure Measurements in Patients at Risk for Acute Compartment Syndrome
NCT04671173
Recruiting
The purpose of this trial is to conduct a pilot study that will aid in the design of an evaluation of the clinical benefit of MY01, an FDA cleared device, that allows continuous monitoring of intracompartmental muscle pressure in patients at risk for developing acute compartment syndrome. MY01 has previously been successfully tested on animal and Human cadaver Acute Compartment Syndrome models within the RI MUHC through Department of Defense research Grant (Combat Casualty Care Research Program... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/04/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Acute Compartment Syndrome
Register for Updates
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
NCT03875183
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: Stern Cardiovascular, Germantown, Tennessee
Conditions: Heart Failure, Reduced Ejection Fraction
Register for Updates
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
NCT04045496
Recruiting
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2022
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
Register for Updates
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
NCT04587479
Recruiting
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2022
Locations: Tennessee Oncology Nashville, Nashville, Tennessee
Conditions: Solid Tumors, Adult
Register for Updates
Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant
NCT03415139
Recruiting
This clinical research studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. Oral glucose tolerance tests (OGTT), hyperglycemic clamps, and immune assays will be used to define the mechanisms associated with abnormal glucose homeostasis following stem cell transplantation. Information from this clinical trial could be used to develop standardized screening procedures or to develop optimal treatment strate... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
03/10/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Diabetes Mellitus, Cancer
Register for Updates
Ruptured Aneurysms Treated With Hydrogel Coils
NCT03252314
Recruiting
To determine safety and occlusion rates when second-generation hydrogel coils are used in the treatment of ruptured intracranial aneurysms.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/08/2022
Locations: Methodist University Hospital, Memphis, Tennessee
Conditions: Ruptured Aneurysm
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Tristar Centennial Medical Center, Nashville, Tennessee
Conditions: Coronary Artery Disease
Register for Updates
NOVOCART®3D for Treatment of Articular Cartilage of the Knee
NCT01957722
Recruiting
This study is to compare NOVOCART 3D relative to Microfracture for the treatment of knee cartilage defects. Efficacy will be evaluated by both pain and function. Safety will also be evaluated.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/01/2022
Locations: Clinical Research Solutions, Jackson, Tennessee
Conditions: Articular Cartilage of the Femoral Condyle Between 2-6cm2
Register for Updates
PEN-866 in Patients With Advanced Solid Malignancies
NCT03221400
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: The West Clinic, Germantown, Tennessee
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Register for Updates
Shared-Decision Making for Hydroxyurea
NCT03442114
Recruiting
The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences). The study will compare two methods to help clinicians facilitate this-a clinician pocket guide and a clinician hydroxyurea shared decision making toolkit-in a group of parents of children ages 0-5 with sickle cell disease. The investigators hope t... Read More
Gender:
All
Ages:
Between 1 month and 5 years
Trial Updated:
02/09/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Sickle Cell Anemia, Children, Only
Register for Updates
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
NCT03545607
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 115, Chattanooga, Tennessee
Conditions: Ischemic Stroke
Register for Updates